Chemo-radiotherapy for Anal Cancer
Author Information
Author(s): Zampino Maria G, Magni Elena, Leonardi Maria C, Santoro Luigi, Petazzi Elena, Fodor Cristiana, Petralia Giuseppe, Trovato Cristina, Nolè Franco, Orecchia Roberto
Primary Institution: European Institute of Oncology
Hypothesis
To evaluate efficacy and feasibility of chemo-radiotherapy in patients with non-metastatic anal squamous-cell-cancer.
Conclusion
Concurrent cisplatin plus fluorouracil and radiotherapy is associated with favourable local control rates and acute toxicity.
Supporting Evidence
- 93.1% of patients achieved complete remission after treatment.
- The estimated 7-year disease-free survival was 83.4%.
- The estimated 7-year overall survival was 85.7%.
- The rate of colostomy was 14%.
Takeaway
Doctors treated 29 patients with anal cancer using a combination of chemotherapy and radiation, and most of them got better.
Methodology
Patients received pelvic radiotherapy with continuous infusion fluorouracil and cisplatin, followed by additional chemotherapy based on tumor response.
Limitations
The study had a small sample size and was conducted at a single institution.
Participant Demographics
4 males, 25 females; median age 57 years.
Statistical Information
Confidence Interval
95% CI: 78% - 98%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website